Show simple item record

dc.contributor.authorWoollacott, Ione
dc.contributor.authorMorgan, George; orcid: 0000-0003-2014-3415; email: george.morgan@hcdeconomics.com
dc.contributor.authorChowdary, Pratima
dc.contributor.authorO'Hara, Jamie
dc.contributor.authorFranks, Bethany
dc.contributor.authorvan Overbeeke, Eline; orcid: 0000-0003-0073-9350
dc.contributor.authorDunn, Nicola
dc.contributor.authorMichelsen, Sissel
dc.contributor.authorHuys, Isabelle
dc.contributor.authorMartin, Antony; orcid: 0000-0003-4383-6038
dc.contributor.authorCawson, Matthew
dc.contributor.authorBrownrigg, Jack
dc.contributor.authorWinburn, Ian; orcid: 0000-0002-6357-2642
dc.contributor.authorThomson, Jim
dc.date.accessioned2022-07-12T19:00:08Z
dc.date.available2022-07-12T19:00:08Z
dc.date.issued2022-04-19
dc.date.submitted2021-07-14
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/627015/hae.14572.pdf?sequence=2
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/627015/hae.14572.xml?sequence=3
dc.identifier.citationHaemophilia, volume 28, issue 4, page 588-609
dc.identifier.urihttp://hdl.handle.net/10034/627015
dc.descriptionFrom Wiley via Jisc Publications Router
dc.descriptionHistory: received 2021-07-14, rev-recd 2022-04-01, accepted 2022-04-08, pub-electronic 2022-04-19, pub-print 2022-07
dc.descriptionArticle version: VoR
dc.descriptionPublication status: Published
dc.descriptionFunder: Pfizer; Id: http://dx.doi.org/10.13039/100004319
dc.description.abstractAbstract: Introduction: With the development of gene therapy for people with haemophilia (PWH), it is important to understand how people impacted by haemophilia (PIH) and clinicians prioritise haemophilia treatment attributes to support informed treatment decisions. Objective: To examine the treatment attribute preferences of PIH and clinical experts in the United Kingdom (UK) and to develop a profile of gene therapy characteristics fit for use in future discrete choice experiments (DCEs). Methods: Semi‐structured interviews were conducted with PIH (n = 14) and clinical experts (n = 6) who ranked pre‐defined treatment attributes by importance. Framework analysis was conducted to identify key themes and treatment attributes; points were allocated based on the rankings. Synthesis of results by a multidisciplinary group informed development of a profile of gene therapy characteristics for use in future research. Results: Key themes identified by PIH and clinical experts included patient relevant features and the importance of ‘informed decision making'. The six top‐ranked treatment attributes were ‘effect on factor level’ (79 points), ‘uncertainty regarding long‐term risks’ (57 points), ‘impact on daily life’ (41 points), ‘frequency of monitoring’ (33 points), ‘impact on ability to participate in physical activity’ (29 points), and ‘uncertainty regarding long‐term benefits’ (28 points). The final treatment characteristics were categorised as therapeutic option, treatment effectiveness, safety concerns, impact on self‐management and quality of life (role limitations). Conclusion: We identified several gene therapy characteristics important to PIH and clinicians in the UK. These characteristics will be used in a future DCE to further investigate patient preferences for gene therapy.
dc.languageen
dc.rightsLicence for VoR version of this article: http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceissn: 1351-8216
dc.sourceissn: 1365-2516
dc.subjectORIGINAL ARTICLE
dc.subjectORIGINAL ARTICLES
dc.subjectdiscrete choice experiment
dc.subjecthaemophilia
dc.subjectgene therapies
dc.subjectpreferences
dc.subjectqualitative research
dc.subjecttreatment attributes
dc.titleExamining patient and professional perspectives in the UK for gene therapy in haemophilia
dc.typearticle
dc.date.updated2022-07-12T19:00:07Z
dc.date.accepted2022-04-08


Files in this item

Thumbnail
Name:
hae.14572.pdf
Size:
3.080Mb
Format:
PDF
Thumbnail
Name:
hae.14572.xml
Size:
11.47Kb
Format:
XML

This item appears in the following Collection(s)

Show simple item record